Senior Manager, Molecular Research
CurrentCurrently leading a team on improvements to our FDA approved ClonoSEQ assay, which is a measurable residual disease (MRD) test that detects, quantifies, and assesses the small number of cancer cells that may remain in a patient’s body during and after treatment. This very sensitive assay allows physicians to test disease burden over time to pivot therapy.